What is MRD, and why is it important in acute lymphoblastic leukemia?

Sebastian Giebel

During the ESH 3rd How to Diagnose and Treat Acute Leukaemias, Know ALL spoke with Sebastian Giebel, Maria Sklodowska-Curie National Research Institute of Oncology, Gliwice, PL. We asked, What is measurable residual disease (MRD), and why is it important in acute lymphoblastic leukemia?

Giebel begins by discussing detection methods, including flow cytometry or molecular techniques which are used to precisely monitor responses. He highlights the huge prognostic impact MRD can have for patients. Finally, he outlines the bispecific antibody blinatumomab, used as a therapy to eradicate MRD.

All content on Know All is primarily intended for patients and caregivers. If you are a healthcare professional, please visit the ALL Hub.

Please get in touch if you have any questions about Know All or if you would like to discuss a potential collaboration.

Brought to you by

Scientific Education Support

In collaboration with

Thank you to the funders of Know ALL. All content is developed independently by SES in collaboration with an expert ambassador group; funders are allowed no influence on the content of Know ALL.

GOLD

BRONZE